{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:54:23Z","timestamp":1790430863786,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":3907,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1038\/modpathol.2011.211","type":"journal-article","created":{"date-parts":[[2012,1,27]],"date-time":"2012-01-27T15:11:13Z","timestamp":1327677073000},"page":"740-750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":157,"title":["BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Jessica N","family":"McAlpine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"K\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad H","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah M","family":"Prentice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve E","family":"Kalloger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Senz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohrab P","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G","family":"Huntsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Blake","family":"Gilks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/modpathol.2011.211_bib1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2011.211_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2011.211_bib3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.humpath.2008.01.003","article-title":"Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma","volume":"39","author":"Gilks","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1038\/modpathol.2011.211_bib4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1525-1438.2006.00777.x","article-title":"Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects","volume":"17","author":"Ayhan","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1038\/modpathol.2011.211_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000192407.04428.bb","article-title":"Aggressive surgical effort and improved survival in advanced-stage ovarian cancer","volume":"107","author":"Aletti","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1038\/modpathol.2011.211_bib6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1038\/modpathol.2011.211_bib7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ygyno.2007.09.020","article-title":"Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma","volume":"108","author":"Chi","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1038\/modpathol.2011.211_bib8","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ygyno.2006.06.028","article-title":"The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer","volume":"103","author":"Eisenhauer","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1038\/modpathol.2011.211_bib9","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1006\/gyno.2001.6328","article-title":"Identification of prognostic factors in advanced epithelial ovarian carcinoma","volume":"82","author":"Chi","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1038\/modpathol.2011.211_bib10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/0090-8258(83)90055-0","article-title":"Prognostic factors in malignant epithelial ovarian tumors","volume":"15","author":"Sigurdsson","year":"1983","journal-title":"Gynecol Oncol"},{"key":"10.1038\/modpathol.2011.211_bib11","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","article-title":"Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial","volume":"21","author":"Markman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2011.211_bib12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/IGC.0b013e3181a4476b","volume":"19","author":"Gadducci","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1038\/modpathol.2011.211_bib13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ygyno.2009.09.029","article-title":"Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications","volume":"116","author":"K\u00f6bel","year":"2010","journal-title":"Gynecolc Oncol"},{"key":"10.1038\/modpathol.2011.211_bib14","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for III stage epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2011.211_bib15","first-page":"609","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Dressman","year":"2007","journal-title":"Nature"},{"key":"10.1038\/modpathol.2011.211_bib16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/path.2744","article-title":"The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas","volume":"222","author":"K\u00f6bel","year":"2010","journal-title":"J Pathol"},{"key":"10.1038\/modpathol.2011.211_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","article-title":"Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary","volume":"221","author":"Ahmed","year":"2010","journal-title":"J Pathol"},{"key":"10.1038\/modpathol.2011.211_bib18","doi-asserted-by":"crossref","first-page":"e6412","DOI":"10.1371\/journal.pone.0006412","article-title":"Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors","volume":"4","author":"Milne","year":"2009","journal-title":"PloS One"},{"key":"10.1038\/modpathol.2011.211_bib19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/modpathol.2008.191","article-title":"Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss","volume":"22","author":"Clarke","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2011.211_bib20","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-07-4433","article-title":"HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma","volume":"14","author":"Han","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2011.211_bib21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2011.211_bib22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00262-008-0583-5","article-title":"Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer","volume":"58","author":"Leffers","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1038\/modpathol.2011.211_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-065X.2008.00614.x","article-title":"The impact of T-cell immunity on ovarian cancer outcomes","volume":"222","author":"Nelson","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1038\/modpathol.2011.211_bib24","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/modpathol.2011.211_bib25","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/modpathol.2011.211_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2407-8-17","article-title":"Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities","volume":"8","author":"Press","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1038\/modpathol.2011.211_bib27","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2011.211_bib28","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jnci\/94.18.1396","article-title":"Inactivation of BRCA1 and BRCA2 in ovarian cancer","volume":"94","author":"Hilton","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/modpathol.2011.211_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/jnci\/94.1.61","article-title":"Frequency of BRCA1 dysfunction in ovarian cancer","volume":"94","author":"Geisler","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/modpathol.2011.211_bib30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1471-0528.2010.02838.x","article-title":"PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine","volume":"118","author":"Mukhopadhyay","year":"2011","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1038\/modpathol.2011.211_bib31","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev.pathol.3.121806.151422","article-title":"Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment","volume":"4","author":"Venkitaraman","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"10.1038\/modpathol.2011.211_bib32","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1471-4914(02)02434-6","article-title":"The relationship between the roles of BRCA genes in DNA repair and cancer predisposition","volume":"8","author":"Tutt","year":"2002","journal-title":"Trends Mol Med"},{"key":"10.1038\/modpathol.2011.211_bib33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0959-437X(00)00069-1","article-title":"DNA double strand break repair in mammalian cells","volume":"10","author":"Karran","year":"2000","journal-title":"Curr Opin Gen Dev"},{"key":"10.1038\/modpathol.2011.211_bib34","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/cbt.8.7.7968","article-title":"Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo","volume":"8","author":"Tassone","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1038\/modpathol.2011.211_bib35","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2174\/187152008784220267","article-title":"Therapeutic exploitation of tumor cell defects in homologous recombination","volume":"8","author":"Powell","year":"2008","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1038\/modpathol.2011.211_bib36","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-05-0493","article-title":"Chemosensitization to cisplatin by inhibitors of the Fanconi anemia\/BRCA pathway","volume":"5","author":"Chirnomas","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/modpathol.2011.211_bib37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.canlet.2005.12.028","article-title":"Variation in cisplatinum sensitivity is not associated with Fanconi anemia\/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines","volume":"245","author":"Snyder","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1038\/modpathol.2011.211_bib38","doi-asserted-by":"crossref","first-page":"23899","DOI":"10.1074\/jbc.C000276200","article-title":"The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin","volume":"275","author":"Bhattacharyya","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1038\/modpathol.2011.211_bib39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10689-005-2832-5","article-title":"BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis","volume":"5","author":"Foulkes","year":"2006","journal-title":"Fam Cancer"},{"key":"10.1038\/modpathol.2011.211_bib40","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.breast.2007.07.021","article-title":"Using specific cytotoxics with a targeted mind","volume":"16","author":"Di Leo","year":"2007","journal-title":"Breast"},{"key":"10.1038\/modpathol.2011.211_bib41","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.clon.2009.04.004","article-title":"Dramatic response to platinum in a patient with cancer with a germline BRCA2 mutation","volume":"21","author":"Moule","year":"2009","journal-title":"Clin Oncol"},{"key":"10.1038\/modpathol.2011.211_bib42","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u2033BRCAness\u2033 syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations","volume":"26","author":"Tan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2011.211_bib43","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJM199611073351901","article-title":"Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1","volume":"335","author":"Rubin","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2011.211_bib44","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/cncr.11310","article-title":"Improved survival in women with BRCA-associated ovarian carcinoma","volume":"97","author":"Cass","year":"2003","journal-title":"Cancer"},{"key":"10.1038\/modpathol.2011.211_bib45","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"JAMA"},{"key":"10.1038\/modpathol.2011.211_bib46","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/annonc\/mdq577","article-title":"Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity","volume":"22","author":"Gallagher","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1038\/modpathol.2011.211_bib47","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1086\/521032","article-title":"A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes","volume":"81","author":"Easton","year":"2007","journal-title":"Am J Hum Gen"},{"key":"10.1038\/modpathol.2011.211_bib48","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nature08489","article-title":"Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution","volume":"461","author":"Shah","year":"2009","journal-title":"Nature"},{"key":"10.1038\/modpathol.2011.211_bib49","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1038\/modpathol.2011.211_bib50","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/bioinformatics\/btq040","article-title":"SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors","volume":"26","author":"Goya","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1038\/modpathol.2011.211_bib51","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1038\/modpathol.2011.211_bib52","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/cncr.21992","article-title":"Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential","volume":"107","author":"Wiley","year":"2006","journal-title":"Cancer"},{"key":"10.1038\/modpathol.2011.211_bib53","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","article-title":"Ovarian carcinoma subtypes are different diseases: implications for biomarker studies","volume":"5","author":"Kobel","year":"2008","journal-title":"PLoS Med"},{"key":"10.1038\/modpathol.2011.211_bib54","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","article-title":"The genesis and evolution of high-grade serous ovarian cancer","volume":"10","author":"Bowtell","year":"2010","journal-title":"Nat Rev"},{"key":"10.1038\/modpathol.2011.211_bib55","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/PAS.0b013e3181ef7b16","article-title":"Are all pelvic (nonuterine) serous carcinomas of tubal origin?","volume":"34","author":"Przybycin","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/modpathol.2011.211_bib56","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/IGC.0b013e3181dd0110","article-title":"Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer","volume":"20","author":"Mackay","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1038\/modpathol.2011.211_bib57","doi-asserted-by":"crossref","unstructured":"Bolton KL, Goh C, Ramus S, et al. Genetic heterogeneity of ovarian cancer survival effects in BRCA1\/2 germline mutations: a large, multi-center study. Thesis 2011.","DOI":"10.1158\/1538-7445.AM2011-2752"},{"key":"10.1038\/modpathol.2011.211_bib58","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-lable, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1038\/modpathol.2011.211_bib59","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1002\/cncr.24317","article-title":"Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer","volume":"115","author":"Adams","year":"2009","journal-title":"Cancer"},{"key":"10.1038\/modpathol.2011.211_bib60","doi-asserted-by":"crossref","first-page":"7225","DOI":"10.1158\/1078-0432.CCR-07-2222","article-title":"BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease","volume":"13","author":"Cannistra","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2011.211_bib61","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1158\/1078-0432.CCR-07-1083","article-title":"BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy","volume":"13","author":"Quinn","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2011.211_bib62","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1158\/0008-5472.CAN-09-1178","article-title":"Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma","volume":"69","author":"Sakai","year":"2009","journal-title":"Cancer Res"},{"key":"10.1038\/modpathol.2011.211_bib63","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"key":"10.1038\/modpathol.2011.211_bib64","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/modpathol2011211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2011211","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222016222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222016222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2011211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:51:35Z","timestamp":1760230295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222016222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0893395222016222"],"URL":"https:\/\/doi.org\/10.1038\/modpathol.2011.211","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/modpathol.2011.211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}